BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16142366)

  • 1. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
    He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
    Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
    He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
    Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.
    Jagarlamudi KK; Moreau L; Westberg S; Rönnberg H; Eriksson S
    PLoS One; 2015; 10(9):e0137871. PubMed ID: 26366881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
    Jagarlamudi KK; Hansson LO; Eriksson S
    BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
    He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
    Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
    Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
    BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.
    Jagarlamudi KK; Shaw M
    Biomark Med; 2018 Sep; 12(9):1035-1048. PubMed ID: 30039979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma.
    Sharif H; von Euler H; Westberg S; He E; Wang L; Eriksson S
    Vet J; 2012 Oct; 194(1):40-7. PubMed ID: 22516918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum thymidine kinase 1 activity in breast cancer.
    Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
    Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.
    He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):352-8. PubMed ID: 20544519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
    Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
    Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
    Li HX; Lei DS; Wang XQ; Skog S; He Q
    Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.
    Bolayirli M; Papila C; Korkmaz GG; Papila B; Aydoğan F; Karataş A; Uzun H
    J Clin Lab Anal; 2013 May; 27(3):220-6. PubMed ID: 23686779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.
    Wu C; Yang R; Zhou J; Bao S; Zou L; Zhang P; Mao Y; Wu J; He Q
    J Immunol Methods; 2003 Jun; 277(1-2):157-69. PubMed ID: 12799048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feline thymidine kinase 1: molecular characterization and evaluation of its serum form as a diagnostic biomarker.
    Wang L; Sharif H; Saellström S; Rönnberg H; Eriksson S
    BMC Vet Res; 2021 Sep; 17(1):316. PubMed ID: 34579716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
    Nisman B; Allweis T; Kadouri L; Mali B; Hamburger T; Baras M; Gronowitz S; Peretz T
    Clin Chem Lab Med; 2013 Feb; 51(2):439-47. PubMed ID: 23093267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can thymidine kinase levels in breast tumors predict disease recurrence?
    O'Neill KL; Hoper M; Odling-Smee GW
    J Natl Cancer Inst; 1992 Dec; 84(23):1825-8. PubMed ID: 1433372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thymidine kinase 1 protein concentrations and presence of its autoantibody as biomarkers for screening dogs with malignant tumors.
    Kim Y; Park J; Kim B; Yu KR; Kim HS; Oh Y; Seo K; Ryu M; Park C; Bhang D; Choi U; Youn H
    J Vet Intern Med; 2024; 38(1):300-307. PubMed ID: 38088206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
    Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
    Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.